Zoracopan
CAS 2243483-63-6
MF C31H31BrN6O3 MW 615.52
2-Azabicyclo[3.1.0]hexane-3-carboxamide, 2-[2-[3-acetyl-7-methyl-5-(2-methyl-5-pyrimidinyl)-1H-indol-1-yl]acetyl]-N-(6-bromo-3-methyl-2-pyridinyl)-5-methyl-, (1R,3S,5R)-
(1R,3S,5R)-2-{[3-acetyl-7-methyl-5-(2-methylpyrimidin5-yl)-1H-indol-1-yl]acetyl}-N-(6-bromo-3-methylpyridin2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide
complement factor D inhibitor, ALXN-2080, ALXN 2080, E7799Y8LXY
Zoracopan is a selective complement factor D (CFD) inhibitor. When administered systemically (orally or intravenously), Zoracopan accumulates and is sustained-released in ocular tissues, primarily in the choroid-retinal pigment epithelium (C-RPE) and/or iridociliary body (I-CB).
Zoracopan is a small molecule drug. The usage of the INN stem ‘-copan’ in the name indicates that Zoracopan is a complement receptor antagonist/complement inhibitor. Zoracopan is under investigation in clinical trial NCT06173596 (A Study to Evaluate Potential Drug Interactions Between ALXN2080 and Itraconazole, Fluconazole & Carbamazepine in Healthy Adults). Zoracopan has a monoisotopic molecular weight of 614.16 Da.
- Safety and Tolerability, PK, and PD Study of Single and Multiple ALXN2080 Doses in Healthy ParticipantsCTID: NCT05428696Phase: Phase 1Status: CompletedDate: 2024-06-07
- A Study to Evaluate Potential Drug Interactions Between ALXN2080 and Itraconazole, Fluconazole & Carbamazepine in Healthy AdultsCTID: NCT06173596Phase: Phase 1Status: CompletedDate: 2024-06-20
- A Study to Investigate the Potential Drug Interactions Between ALXN2080 and Rosuvastatin and Metformin in Healthy Adult ParticipantsCTID: NCT06160414Phase: Phase 1Status: CompletedDate: 2025-04-24
SYN
426
https://patentscope.wipo.int/search/en/detail.jsf?docId=US289331902&_cid=P10-MJJEYB-31207-1
SYN
SYN
https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2018160889&_cid=P10-MJJEK1-12570-1
PAT
- Aryl, heteroaryl and heterocyclic pharmaceutical compounds for the treatment of medical disordersPublication Number: JP-7390449-B2Priority Date: 2017-03-01Grant Date: 2023-12-01
- Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disordersPublication Number: US-11708351-B2Priority Date: 2017-03-01Grant Date: 2023-07-25
- Aryl, heteroaryl and heterocyclic pharmaceutical compounds for the treatment of medical disordersPublication Number: JP-2022174122-APriority Date: 2017-03-01
- Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for the treatment of medical disordersPublication Number: KR-20190126831-APriority Date: 2017-03-01
- Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disordersPublication Number: US-11084800-B2Priority Date: 2017-03-01Grant Date: 2021-08-10
- Aryl, heteroary, and heterocyclic pharmaceutical compounds for treatment of medical disordersPublication Number: EP-3985002-A1Priority Date: 2017-03-01
- Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for the treatment of medical disordersPublication Number: KR-102632860-B1Priority Date: 2017-03-01Grant Date: 2024-02-02
- Aryi, Heteroaryl, and Heterocyclic Pharmaceutical Compounds for Treatment of Medical DisordersPublication Number: US-2020071301-A1Priority Date: 2017-03-01
- Aryl, Heteroaryl and Heterocyclic Pharmaceutical Compounds for the Treatment of Medical DisordersPublication Number: CN-110603252-APriority Date: 2017-03-01
- Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disordersPublication Number: US-2022396563-A1Priority Date: 2017-03-01
- Ocular drug depot for complement-mediated disordersPublication Number: US-2023126447-A1Priority Date: 2020-03-10
- Ocular drug depot for complement-mediated disordersPublication Number: WO-2021183555-A1Priority Date: 2020-03-10
- Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disordersPublication Number: US-12162860-B2Priority Date: 2017-03-01Grant Date: 2024-12-10
- Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disordersPublication Number: US-2023357199-A1Priority Date: 2017-03-01
- Aryl, heteroary, and heterocyclic pharmaceutical compounds for treatment of medical disordersPublication Number: WO-2018160889-A1Priority Date: 2017-03-01
AS ON OCT2025 4.511 LAKHS VIEWS ON BLOG WORLDREACH AVAILABLEFOR YOUR ADVERTISEMENT
join me on Linkedin
Anthony Melvin Crasto Ph.D – India | LinkedIn
join me on Researchgate
RESEARCHGATE
join me on Facebook
Anthony Melvin Crasto Dr. | Facebook
join me on twitter
Anthony Melvin Crasto Dr. | twitter
+919321316780 call whatsaapp
EMAIL. amcrasto@gmail.com
……
////zoracopan, complement factor D inhibitor, ALXN-2080, ALXN 2080, E7799Y8LXY